Literature DB >> 9809507

Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria.

H E Möller1, J Weglage, D Wiedermann, K Ullrich.   

Abstract

In vivo nuclear magnetic resonance spectroscopy can be used to measure intracerebral phenylalanine (Phe) concentrations in patients with phenylketonuria (PKU). Stationary levels, obtained under free nutrition, as well as time courses after an oral Phe load (100 mg/kg) were investigated in 11 PKU patients and were correlated with the individual clinical outcome. At blood levels around 1.2 mmol/L, brain Phe was 0.41 to 0.73 mmol/L in clinically "typical" patients, but less than 0.15 mmol/L in three untreated, normally intelligent, adult women. Kinetic investigations revealed higher transport Michaelis constants and lower ratios of the brain influx and consumption rates in these women than in the "typical" control patients (Kt,app = 0.45 to 1.10 mmol/L versus 0.10 mmol/L; T(max)/v(met) = 2.55 to 3.19 versus 7.8 to 14.0). Such variations seem to be major causative factors for the individual vulnerability to PKU.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809507     DOI: 10.1097/00004647-199811000-00004

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  22 in total

1.  Neurological deterioration in adult phenylketonuria.

Authors:  J Weglage; C Oberwittler; T Marquardt; J Schellscheidt; A von Teeffelen-Heithoff; G Koch; H Gerding
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

2.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

Review 3.  Biological and social influences on cognitive control processes dependent on prefrontal cortex.

Authors:  Adele Diamond
Journal:  Prog Brain Res       Date:  2011       Impact factor: 2.453

Review 4.  Garrod's foresight; our hindsight.

Authors:  C R Scriver
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 5.  MR spectroscopy: a powerful tool for investigating brain function and neurological diseases.

Authors:  A P Burlina; T Aureli; F Bracco; F Conti; L Battistin
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

6.  Prolactin, a marker for cerebral dopamine deficiency in patients suffering from phenylketonuria (PKU)?

Authors:  J Denecke; W Schlegel; G H Koch; R Feldmann; E Harms; J Weglage
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

Review 7.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

8.  Biochemical correlates of neuropsychiatric illness in maple syrup urine disease.

Authors:  Emilie R Muelly; Gregory J Moore; Scott C Bunce; Julie Mack; Don C Bigler; D Holmes Morton; Kevin A Strauss
Journal:  J Clin Invest       Date:  2013-03-08       Impact factor: 14.808

9.  Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.

Authors:  J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; H E Möller
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

10.  1H MR chemical shift imaging detection of phenylalanine in patients suffering from phenylketonuria (PKU).

Authors:  Paul E Sijens; Matthijs Oudkerk; Dirk-Jan Reijngoud; Klaas L Leenders; Harold W de Valk; Francjan J van Spronsen
Journal:  Eur Radiol       Date:  2004-08-03       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.